BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 32591432)

  • 1. Lung metastases share common immune features regardless of primary tumor origin.
    García-Mulero S; Alonso MH; Pardo J; Santos C; Sanjuan X; Salazar R; Moreno V; Piulats JM; Sanz-Pamplona R
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32591432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastases.
    Tabariès S; Ouellet V; Hsu BE; Annis MG; Rose AA; Meunier L; Carmona E; Tam CE; Mes-Masson AM; Siegel PM
    Breast Cancer Res; 2015 Mar; 17(1):45. PubMed ID: 25882816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
    Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
    Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 Expression of Lung Cancer Cells, Unlike Infiltrating Immune Cells, Is Stable and Unaffected by Therapy During Brain Metastasis.
    Téglási V; Pipek O; Lózsa R; Berta K; Szüts D; Harkó T; Vadász P; Rojkó L; Döme B; Bagó AG; Tímár J; Moldvay J; Szállási Z; Reiniger L
    Clin Lung Cancer; 2019 Sep; 20(5):363-369.e2. PubMed ID: 31178388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune suppressive microenvironment in brain metastatic non-small cell lung cancer: comprehensive immune microenvironment profiling of brain metastases versus paired primary lung tumors (GASTO 1060).
    Li M; Hou X; Sai K; Wu L; Chen J; Zhang B; Wang N; Wu L; Zheng H; Zhang J; Mou Y; Chen L
    Oncoimmunology; 2022; 11(1):2059874. PubMed ID: 35402080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes.
    Ligon JA; Choi W; Cojocaru G; Fu W; Hsiue EH; Oke TF; Siegel N; Fong MH; Ladle B; Pratilas CA; Morris CD; Levin A; Rhee DS; Meyer CF; Tam AJ; Blosser R; Thompson ED; Suru A; McConkey D; Housseau F; Anders R; Pardoll DM; Llosa N
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in PD-L1 expression on tumor and immune cells between lung metastases and corresponding primary tumors.
    Takamori S; Takada K; Tagawa T; Toyokawa G; Hirai F; Yamashita N; Okamoto T; Oki E; Yoshizumi T; Oda Y; Maehara Y
    Surg Oncol; 2018 Dec; 27(4):637-641. PubMed ID: 30449485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer.
    Wen WX; Leong CO
    PLoS One; 2019; 14(4):e0215381. PubMed ID: 31022191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features.
    Sia D; Jiao Y; Martinez-Quetglas I; Kuchuk O; Villacorta-Martin C; Castro de Moura M; Putra J; Camprecios G; Bassaganyas L; Akers N; Losic B; Waxman S; Thung SN; Mazzaferro V; Esteller M; Friedman SL; Schwartz M; Villanueva A; Llovet JM
    Gastroenterology; 2017 Sep; 153(3):812-826. PubMed ID: 28624577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer.
    Mansfield AS; Aubry MC; Moser JC; Harrington SM; Dronca RS; Park SS; Dong H
    Ann Oncol; 2016 Oct; 27(10):1953-8. PubMed ID: 27502709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed death ligand 1 expression and CD8
    Zhou J; Gong Z; Jia Q; Wu Y; Yang ZZ; Zhu B
    Biochem Biophys Res Commun; 2018 Apr; 498(4):751-757. PubMed ID: 29526752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors.
    Kim R; Keam B; Kim S; Kim M; Kim SH; Kim JW; Kim YJ; Kim TM; Jeon YK; Kim DW; Chung DH; Lee JS; Heo DS
    BMC Cancer; 2019 Jan; 19(1):19. PubMed ID: 30616523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape.
    Faruki H; Mayhew GM; Serody JS; Hayes DN; Perou CM; Lai-Goldman M
    J Thorac Oncol; 2017 Jun; 12(6):943-953. PubMed ID: 28341226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context.
    Wiesweg M; Mairinger F; Reis H; Goetz M; Kollmeier J; Misch D; Stephan-Falkenau S; Mairinger T; Walter RFH; Hager T; Metzenmacher M; Eberhardt WEE; Zaun G; Köster J; Stuschke M; Aigner C; Darwiche K; Schmid KW; Rahmann S; Schuler M
    Eur J Cancer; 2020 Nov; 140():76-85. PubMed ID: 33059196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed Death Receptor Ligand One Expression May Independently Predict Survival in Patients With Non-Small Cell Lung Carcinoma Brain Metastases Receiving Immunotherapy.
    Hulsbergen AFC; Mammi M; Nagtegaal SHJ; Lak AM; Kavouridis V; Smith TR; Iorgulescu JB; Mekary RA; Verhoeff JJC; Broekman MLD; Phillips JG
    Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):258-267. PubMed ID: 32335185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Organ-specific heterogeneity in tumor-infiltrating immune cells and cancer antigen expression in primary and autologous metastatic lung adenocarcinoma.
    Restle D; Dux J; Li X; Byun AJ; Choe JK; Li Y; Vaghjiani RG; Thomas C; Misawa K; Tan KS; Jones DR; Chintala NK; Adusumilli PS
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37349126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of Programmed Cell Death Ligand 1 and Associated Lymphocyte Infiltration in Olfactory Neuroblastoma.
    London NR; Rooper LM; Bishop JA; Xu H; Bernhardt LJ; Ishii M; Hann CL; Taube JM; Izumchenko E; Gaykalova DA; Gallia GL
    World Neurosurg; 2020 Mar; 135():e187-e193. PubMed ID: 31785431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-1/PD-L1 and immune-related gene expression pattern in pediatric malignant brain tumors: clinical correlation with survival data in Korean population.
    Hwang K; Koh EJ; Choi EJ; Kang TH; Han JH; Choe G; Park SH; Yearley JH; Annamalai L; Blumenschein W; Sathe M; McClanahan T; Jung H; Wang KC; Kim SK; Kim CY
    J Neurooncol; 2018 Sep; 139(2):281-291. PubMed ID: 29730815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The immune microenvironment in non-small cell lung cancer is predictive of prognosis after surgery.
    Öjlert ÅK; Halvorsen AR; Nebdal D; Lund-Iversen M; Solberg S; Brustugun OT; Lingjaerde OC; Helland Å
    Mol Oncol; 2019 May; 13(5):1166-1179. PubMed ID: 30854794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.